Immunotherapies have made important advancements in oncology by expanding treatment options and demonstrating clinical benefits across many different cancer types.
For metastatic non-small cell lung cancer (NSCLC), treatments are evolving and the options available are increasing with the release of key clinical trial results. PD-L1 is a widely validated biomarker assay, which serves as a therapeutic target in this cancer type.
For previously untreated unresectable Malignant Pleural Mesothelioma (MPM), nivolumab plus ipilimumab is the only immunotherapy treatment approved by Health Canada.
This program explores the benefits and limitations of immunotherapy treatment options as well as theimportant clinical trials that have helped to guide their use in the management of metastatic NSCLC and MPM.
This program has received an educational grant or in-kind support from BMS.